AKT1 and leukemia: These results are consistent with the finding that compared with targeting individual components of the PI3K/AKT signaling module alone, inhibition of this pathway at multiple levels using dual-specificity inhibitors, or combining specific pathway inhibitors with classic regimens may be more effective for leukemia therapy [49].